Machine Learning Approaches to Predict 6-Month Mortality Among Patients With Cancer.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
02 10 2019
Historique:
entrez: 26 10 2019
pubmed: 28 10 2019
medline: 17 6 2020
Statut: epublish

Résumé

Machine learning algorithms could identify patients with cancer who are at risk of short-term mortality. However, it is unclear how different machine learning algorithms compare and whether they could prompt clinicians to have timely conversations about treatment and end-of-life preferences. To develop, validate, and compare machine learning algorithms that use structured electronic health record data before a clinic visit to predict mortality among patients with cancer. Cohort study of 26 525 adult patients who had outpatient oncology or hematology/oncology encounters at a large academic cancer center and 10 affiliated community practices between February 1, 2016, and July 1, 2016. Patients were not required to receive cancer-directed treatment. Patients were observed for up to 500 days after the encounter. Data analysis took place between October 1, 2018, and September 1, 2019. Logistic regression, gradient boosting, and random forest algorithms. Primary outcome was 180-day mortality from the index encounter; secondary outcome was 500-day mortality from the index encounter. Among 26 525 patients in the analysis, 1065 (4.0%) died within 180 days of the index encounter. Among those who died, the mean age was 67.3 (95% CI, 66.5-68.0) years, and 500 (47.0%) were women. Among those who were alive at 180 days, the mean age was 61.3 (95% CI, 61.1-61.5) years, and 15 922 (62.5%) were women. The population was randomly partitioned into training (18 567 [70.0%]) and validation (7958 [30.0%]) cohorts at the patient level, and a randomly selected encounter was included in either the training or validation set. At a prespecified alert rate of 0.02, positive predictive values were higher for the random forest (51.3%) and gradient boosting (49.4%) algorithms compared with the logistic regression algorithm (44.7%). There was no significant difference in discrimination among the random forest (area under the receiver operating characteristic curve [AUC], 0.88; 95% CI, 0.86-0.89), gradient boosting (AUC, 0.87; 95% CI, 0.85-0.89), and logistic regression (AUC, 0.86; 95% CI, 0.84-0.88) models (P for comparison = .02). In the random forest model, observed 180-day mortality was 51.3% (95% CI, 43.6%-58.8%) in the high-risk group vs 3.4% (95% CI, 3.0%-3.8%) in the low-risk group; at 500 days, observed mortality was 64.4% (95% CI, 56.7%-71.4%) in the high-risk group and 7.6% (7.0%-8.2%) in the low-risk group. In a survey of 15 oncology clinicians with a 52.1% response rate, 100 of 171 patients (58.8%) who had been flagged as having high risk by the gradient boosting algorithm were deemed appropriate for a conversation about treatment and end-of-life preferences in the upcoming week. In this cohort study, machine learning algorithms based on structured electronic health record data accurately identified patients with cancer at risk of short-term mortality. When the gradient boosting algorithm was applied in real time, clinicians believed that most patients who had been identified as having high risk were appropriate for a timely conversation about treatment and end-of-life preferences.

Identifiants

pubmed: 31651973
pii: 2753527
doi: 10.1001/jamanetworkopen.2019.15997
pmc: PMC6822091
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1915997

Subventions

Organisme : NIGMS NIH HHS
ID : T32 GM075766
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009615
Pays : United States

Références

Clin Transl Gastroenterol. 2014 Jan 02;5:e44
pubmed: 24384866
Stat Med. 2005 Sep 30;24(18):2873-93
pubmed: 16134144
J Clin Oncol. 2004 Dec 15;22(24):4907-17
pubmed: 15520054
JCO Clin Cancer Inform. 2018 Dec;2:1-11
pubmed: 30652575
Ann R Coll Surg Engl. 2015 Mar;97(2):137-9
pubmed: 25723691
J Palliat Med. 2014 Jun;17(6):673-82
pubmed: 24742212
BMJ. 2000 Feb 19;320(7233):469-72
pubmed: 10678857
JAMA Cardiol. 2019 Apr 1;4(4):375-379
pubmed: 30840023
Br J Cancer. 2017 Aug 22;117(5):744-751
pubmed: 28728168
Cancer. 2010 Feb 15;116(4):998-1006
pubmed: 20066693
J Clin Oncol. 2012 May 10;30(14):1715-24
pubmed: 22493340
JAMA Intern Med. 2016 Dec 1;176(12):1863-1865
pubmed: 27695853
J Clin Oncol. 2017 Jan;35(1):96-112
pubmed: 28034065
J Gen Intern Med. 2019 Sep;34(9):1841-1847
pubmed: 31313110
J Oncol Pract. 2019 Jan;15(1):e65-e73
pubmed: 30543761
JAMA. 1998 Jun 3;279(21):1709-14
pubmed: 9624023
JAMA Intern Med. 2017 Mar 1;177(3):407-419
pubmed: 28097303
Palliat Med. 2014 Sep;28(8):1000-25
pubmed: 24651708
J Gen Intern Med. 2018 Jun;33(6):921-928
pubmed: 29383551
Ann Intern Med. 2015 Jan 6;162(1):55-63
pubmed: 25560714
PLoS One. 2017 Apr 4;12(4):e0174944
pubmed: 28376093
Support Care Cancer. 1999 May;7(3):128-33
pubmed: 10335930
Am J Gastroenterol. 2013 Nov;108(11):1723-30
pubmed: 24169273
JAMA Netw Open. 2018 Jul 6;1(3):e180926
pubmed: 30646043
Med Care. 1998 Jan;36(1):8-27
pubmed: 9431328
JAMA Netw Open. 2019 Oct 2;2(10):e1915997
pubmed: 31651973
Epidemiology. 2010 Jan;21(1):128-38
pubmed: 20010215
JAMA. 2008 Oct 8;300(14):1665-73
pubmed: 18840840
BMJ. 2000 Feb 19;320(7233):473
pubmed: 10722295

Auteurs

Ravi B Parikh (RB)

Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
Abramson Cancer Center, University of Pennsylvania, Philadelphia.
Penn Center for Cancer Care Innovation, University of Pennsylvania, Philadelphia.
Department of Medical Ethics and Health Policy, University of Pennsylvania, Philadelphia.
Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania.

Christopher Manz (C)

Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
Abramson Cancer Center, University of Pennsylvania, Philadelphia.
Penn Center for Cancer Care Innovation, University of Pennsylvania, Philadelphia.

Corey Chivers (C)

Penn Medicine, University of Pennsylvania, Philadelphia.

Susan Harkness Regli (SH)

Penn Medicine, University of Pennsylvania, Philadelphia.

Jennifer Braun (J)

Abramson Cancer Center, University of Pennsylvania, Philadelphia.

Michael E Draugelis (ME)

Penn Medicine, University of Pennsylvania, Philadelphia.

Lynn M Schuchter (LM)

Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
Abramson Cancer Center, University of Pennsylvania, Philadelphia.
Penn Center for Cancer Care Innovation, University of Pennsylvania, Philadelphia.

Lawrence N Shulman (LN)

Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
Abramson Cancer Center, University of Pennsylvania, Philadelphia.
Penn Center for Cancer Care Innovation, University of Pennsylvania, Philadelphia.

Amol S Navathe (AS)

Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
Department of Medical Ethics and Health Policy, University of Pennsylvania, Philadelphia.
Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania.

Mitesh S Patel (MS)

Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania.

Nina R O'Connor (NR)

Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
Abramson Cancer Center, University of Pennsylvania, Philadelphia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH